Home › Compare › STAB vs RYLD

STAB vs RYLD: Dividend Comparison 2026

STAB yields 500000.00% · RYLD yields 12.39%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 STAB wins by $4.663521010693878e+33M in total portfolio value
10 years
STAB
STAB
● Live price
500000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.663521010693878e+33M
Annual income
$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00
Full STAB calculator →
RYLD
RYLD
● Live price
12.39%
Share price
$14.64
Annual div
$1.81
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$45.3K
Annual income
$2,682.98
Full RYLD calculator →

Portfolio growth — STAB vs RYLD

📍 STAB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSTABRYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, STAB + RYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
STAB pays
RYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

STAB
Annual income on $10K today (after 15% tax)
$42,500,000.00/yr
After 10yr DRIP, annual income (after tax)
$3,962,433,917,637,946,000,000,000,000,000,000,000,000.00/yr
RYLD
Annual income on $10K today (after 15% tax)
$1,053.44/yr
After 10yr DRIP, annual income (after tax)
$2,280.53/yr
At 15% tax rate, STAB beats the other by $3,962,433,917,637,946,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of STAB + RYLD for your $10,000?

STAB: 50%RYLD: 50%
100% RYLD50/50100% STAB
Portfolio after 10yr
$2.331760505346939e+33M
Annual income
$2,330,843,480,963,498,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.96%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

STAB buys
0
RYLD buys
0
No recent congressional trades found for STAB or RYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSTABRYLD
Forward yield500000.00% ✓12.39%
Annual dividend / share$2.00 ✓$1.81
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$4.663521010693878e+33M$45.3K ✓
Annual income after 10y$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00 ✓$2,682.98
Total dividends collected$4.6634009849658873e+33M$19.4K ✓
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: STAB vs RYLD ($10,000, DRIP)

YearSTAB PortfolioSTAB Income/yrRYLD PortfolioRYLD Income/yrGap
1← crossover$50,010,700$50,000,000.00$11,939$1,239.34+$50.00M → STAB
2$233,748,371,262$233,694,859,813.08$14,158$1,382.89+$233748.36M → STAB
3$1,021,074,511,412,696$1,020,824,400,655,446.10$16,682$1,532.59+$1021074511.40M → STAB
4$4,168,597,328,794,951,700$4,167,504,779,067,739,000.00$19,537$1,687.64+$4168597328794.93M → STAB
5$15,905,475,114,600,665,000,000$15,901,014,715,458,854,000,000.00$22,752$1,847.20+$15905475114600664.00M → STAB
6$56,718,938,532,531,060,000,000,000$56,701,919,674,158,435,000,000,000.00$26,355$2,010.43+$56718938532531060736.00M → STAB
7$189,031,807,435,623,860,000,000,000,000$188,971,118,171,394,040,000,000,000,000.00$30,376$2,176.45+$1.8903180743562385e+23M → STAB
8$588,799,810,476,518,260,000,000,000,000,000$588,597,546,442,562,100,000,000,000,000,000.00$34,847$2,344.43+$5.8879981047651824e+26M → STAB
9$1,714,064,268,114,722,600,000,000,000,000,000,000$1,713,434,252,317,512,700,000,000,000,000,000,000.00$39,800$2,513.54+$1.7140642681147225e+30M → STAB
10$4,663,521,010,693,878,300,000,000,000,000,000,000,000$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00$45,269$2,682.98+$4.663521010693878e+33M → STAB

STAB vs RYLD: Complete Analysis 2026

STAB — Stock

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as expanding into fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. The company is based in Fort Collins, Colorado.

Full STAB Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →
📬

Get this STAB vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

STAB vs SCHDSTAB vs JEPISTAB vs OSTAB vs KOSTAB vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.